These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31759136)

  • 1. Synaptic zinc contributes to motor and cognitive deficits in 6-hydroxydopamine mouse models of Parkinson's disease.
    Sikora J; Kieffer BL; Paoletti P; Ouagazzal AM
    Neurobiol Dis; 2020 Feb; 134():104681. PubMed ID: 31759136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synaptic Zinc: An Emerging Player in Parkinson's Disease.
    Sikora J; Ouagazzal AM
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
    Sheline CT; Zhu J; Zhang W; Shi C; Cai AL
    Neurodegener Dis; 2013; 11(1):49-58. PubMed ID: 22627004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular Zn
    Tamano H; Nishio R; Morioka H; Takeda A
    Mol Neurobiol; 2019 Jan; 56(1):435-443. PubMed ID: 29705946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMDA receptors are altered in the substantia nigra pars reticulata and their blockade ameliorates motor deficits in experimental parkinsonism.
    Sitzia G; Mantas I; Zhang X; Svenningsson P; Chergui K
    Neuropharmacology; 2020 Sep; 174():108136. PubMed ID: 32474027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion.
    Kikuchi Y; Yasuhara T; Agari T; Kondo A; Kuramoto S; Kameda M; Kadota T; Baba T; Tajiri N; Wang F; Tayra JT; Liang H; Miyoshi Y; Borlongan CV; Date I
    J Cell Physiol; 2011 May; 226(5):1390-8. PubMed ID: 20945350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson's disease.
    Chen HH; Chang PC; Chen C; Chan MH
    Pharmacol Rep; 2018 Aug; 70(4):668-676. PubMed ID: 29909247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease.
    Divito CB; Steece-Collier K; Case DT; Williams SP; Stancati JA; Zhi L; Rubio ME; Sortwell CE; Collier TJ; Sulzer D; Edwards RH; Zhang H; Seal RP
    J Neurosci; 2015 Nov; 35(45):14983-99. PubMed ID: 26558771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson's disease.
    Darvas M; Henschen CW; Palmiter RD
    Neurobiol Dis; 2014 May; 65():112-23. PubMed ID: 24491966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson's disease.
    Ikeda-Matsuo Y; Miyata H; Mizoguchi T; Ohama E; Naito Y; Uematsu S; Akira S; Sasaki Y; Tanabe M
    Neurobiol Dis; 2019 Apr; 124():81-92. PubMed ID: 30423474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
    Winkler C; Kirik D; Björklund A; Cenci MA
    Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
    Ztaou S; Maurice N; Camon J; Guiraudie-Capraz G; Kerkerian-Le Goff L; Beurrier C; Liberge M; Amalric M
    J Neurosci; 2016 Aug; 36(35):9161-72. PubMed ID: 27581457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential enhancement of ERK, PKA and Ca
    Mariani LL; Longueville S; Girault JA; Hervé D; Gervasi N
    Neurobiol Dis; 2019 Oct; 130():104506. PubMed ID: 31220556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SK channel blockade reverses cognitive and motor deficits induced by nigrostriatal dopamine lesions in rats.
    Chen L; Deltheil T; Turle-Lorenzo N; Liberge M; Rosier C; Watabe I; Sreng L; Amalric M; Mourre C
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1295-306. PubMed ID: 24661728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease.
    Kopalli SR; Noh SJ; Koppula S; Suh YH
    Neurotoxicology; 2013 Jan; 34():25-32. PubMed ID: 23068419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Ip CW; Beck SK; Volkmann J
    J Neural Transm (Vienna); 2015 Dec; 122(12):1633-43. PubMed ID: 26290125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.